Dr. Rajendra Prasad Centre for Ophthalmic Sciences, All India Institute of Medical Sciences, New Delhi, India.
Indian J Ophthalmol. 2011 May-Jun;59(3):185-9. doi: 10.4103/0301-4738.81021.
The aim was to evaluate the outcome of Ahmed glaucoma valve (AGV) in post-penetrating-keratoplasty glaucoma (PKPG).
In this prospective study, 20 eyes of 20 adult patients with post-PKPG with intraocular pressure (IOP) >21 mmHg, on two or more antiglaucoma medications, underwent AG (model FP7) implantation and were followed up for a minimum of 6 months. Absolute success was defined as 5 < IOP < 21 mmHg and qualified success as 5 < IOP < 21 mmHg with medications or minor procedures.
The mean IOP decreased from 42.95 ± 10.24 to 17.69 ± 3.64 mmHg (P < 0.001) and the use of medications dropped from 2.92 to 0.39 (P < 0.001) after AGV implantation. The absolute success was achieved in 11 eyes and qualified success in 9. There was no significant change in best corrected visual acuity, graft clarity, or graft thickness. Six device-related complications occurred after AGV implantations which were successfully managed with medical or minor surgical therapy.
Postkeratoplasty refractory glaucoma managed by AGV implantation revealed a satisfactory outcome up to 6 months of follow-up.
评估 Ahmed 青光眼阀（AGV）在穿透性角膜移植术后青光眼（PKPG）中的疗效。
在这项前瞻性研究中，20 例成人 PKPG 伴眼内压（IOP）>21mmHg、使用两种或两种以上抗青光眼药物的患者接受了 AG（FP7 型）植入，并至少随访 6 个月。绝对成功定义为 5<IOP<21mmHg，且无需药物或小手术干预；合格成功定义为 5<IOP<21mmHg，但需要药物或小手术。
AGV 植入后，平均 IOP 从 42.95±10.24mmHg 降至 17.69±3.64mmHg（P<0.001），药物使用量从 2.92 降至 0.39（P<0.001）。11 只眼达到绝对成功，9 只眼达到合格成功。最佳矫正视力、移植物清晰度或移植物厚度均无显著变化。AGV 植入后发生 6 例与器械相关的并发症，经药物或小手术治疗后均得到成功处理。
AGV 植入治疗角膜移植后难治性青光眼，在 6 个月的随访中显示出令人满意的结果。
